Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Acquisitions & Divestments (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Change in Acquisitions & Divestments for 12 consecutive years, with $11.2 million as the latest value for Q1 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments changed N/A to $11.2 million in Q1 2025 year-over-year; TTM through Sep 2025 was $11.2 million, a N/A change, with the full-year FY2022 number at $2.5 million, down 94.89% from a year prior.
  • Change in Acquisitions & Divestments was $11.2 million for Q1 2025 at Gyre Therapeutics, up from $2.5 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $27.6 million in Q1 2021 to a low of $2.5 million in Q1 2022.
  • A 3-year average of $10.5 million and a median of $9.3 million in 2021 define the central range for Change in Acquisitions & Divestments.
  • Biggest YoY gain for Change in Acquisitions & Divestments was 17.56% in 2021; the steepest drop was 91.44% in 2021.
  • Gyre Therapeutics' Change in Acquisitions & Divestments stood at $2.9 million in 2021, then decreased by 12.63% to $2.5 million in 2022, then surged by 346.88% to $11.2 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Change in Acquisitions & Divestments are $11.2 million (Q1 2025), $2.5 million (Q1 2022), and $2.9 million (Q4 2021).